# Vicky Makker

Source: https://onco.cc/people/vicky-makker/  
OnCo record `vicky-makker` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

New York oncologist who led KEYNOTE-775, the trial that established lenvatinib plus pembrolizumab for advanced endometrial cancer after chemotherapy.

## Summary

Vicky Makker is a gynaecologic medical oncologist at Memorial Sloan Kettering Cancer Center. She led the phase 2 study and was first author of the 2022 New England Journal of Medicine report of KEYNOTE-775, the phase 3 trial in which lenvatinib plus pembrolizumab improved progression-free and overall survival compared with chemotherapy in advanced endometrial cancer after platinum-based therapy, including mismatch repair-proficient tumours.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: endometrial; gynaecological; immunotherapy; trialist
- Role: Gynaecologic medical oncologist, Memorial Sloan Kettering Cancer Center
- Specialisms: Endometrial cancer; Immunotherapy combinations; Targeted therapy

## Connected records

- cancers: [Advanced or recurrent endometrial cancer](https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/), [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- key papers: [KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer](https://onco.cc/key-papers/paper-keynote-775-nejm-2022/)

---
JSON: https://onco.cc/api/v1/entities/vicky-makker.json